Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.

multiple myeloma
minimal residual disease
residual disease
induction therapy
  • 0 views
  • 19 Feb, 2024
A Study of CC-98633 BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to …

thalidomide
refractory multiple myeloma
proteasome inhibitor
immunotherapeutic agent
pomalidomide
  • 0 views
  • 19 Feb, 2024
TPM Regimen (Thalidomide Prednisone and Methotrexate) in LGLL

Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia. Both T-LGLL and CLPD-NK are indolent disease and share similar biology and clinical course, and treated under the same strategy.

clpd-nk
methotrexate
lymphoid leukemia
lymphoproliferative disorder
t-cell large granular lymphocytic leukemia
  • 0 views
  • 19 Feb, 2024
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

waldenstrom's macroglobulinemia
venetoclax
igm level
ibrutinib
bone marrow biopsy
  • 0 views
  • 19 Feb, 2024
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by …

opioid use
lymphoma
multiple myeloma
high-dose chemotherapy
high dose chemotherapy
  • 0 views
  • 19 Feb, 2024
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

cellular therapy
lymphoma
renal function
cancer chemotherapy
cell therapy
  • 0 views
  • 19 Feb, 2024
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

cell transplantation
cellular therapy
refractory multiple myeloma
renal function
cells therapy
  • 0 views
  • 19 Feb, 2024
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

cell transplantation
cellular therapy
refractory multiple myeloma
renal function
cells therapy
  • 0 views
  • 19 Feb, 2024
A Prospective Non-interventional Multinational Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression free survival (PFS), PFS rate (PFSR), duration of response (DoR), time to response, time and intent to …

isatuximab
refractory multiple myeloma
multiple myeloma
complete resection
carcinoma
  • 0 views
  • 19 Feb, 2024
  • 10 locations
Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.

Multiple myeloma (MM) is a malignancy of plasma cells engaging in monoclonal immunoglobulin production. A strong presumption was established between exposure to pesticides and the risk of MM. The French West Indies departments of Guadeloupe and Martinique are characterized by a wide use of pesticides related to bananas plantation, particularly …

multiple myeloma
monoclonal protein
cancer
monoclonal antibodies
immunoglobulins
  • 0 views
  • 19 Feb, 2024